ProBioGen has signed an agreement with Emergent BioSolutions for a non-exclusive multi-product license and option agreement under which Emergent will be granted access to ProBioGen’s avian AGE1.CR cell line. Financial terms were not disclosed.
Emergent previously had an exclusive license to four indications and is now extended to include additional infectious disease targets, with the option to expand to numerous further indications. The commercial licenses include milestones and royalty payments.
Volker Sandig, chief scientific officer, said, “Innovative medicines against infectious diseases are urgently needed. We are convinced that the combination of ProBioGen’s AGE1.CR cell line for production of MVA-based vaccines together with Emergent’s product development, manufacturing and marketing expertise will yield novel preventive and therapeutic products."